Search results for "Low-dose chemotherapy"

showing 3 items of 3 documents

FAP-related desmoid tumours treated with low dose chemotherapy: Results from a multicentre retrospective analysis.

2018

11556Background: Desmoid tumours (DTs) are monoclonal neoplasms with fibroblastic-myofibroblastic differentiation and they represent the most common extra-intestinal manifestation of familial adeno...

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtybusiness.industrybody regions03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyLow-dose chemotherapy030220 oncology & carcinogenesisInternal medicineMonoclonalmedicineRetrospective analysisDesmoid tumoursbusinessJournal of Clinical Oncology
researchProduct

Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: Results from an international, multi-institutional, retro…

2019

[Introduction] Desmoid tumour (DT) is a locally aggressive fibroblastic proliferative disease representing the most common extraintestinal manifestation of familial adenomatosis polyposis (FAP). As data on the activity of chemotherapy in these patients are limited, we examined the outcomes of patients treated with low-dose methotrexate (MTX)+vinca alkaloids (vinorelbine or vinblastine).

Adultfamilial adenomatosis polyposiCancer Researchmedicine.medical_specialtyVincaAdolescentVinca alkaloidsdesmoidmedicine.medical_treatmentPopulationVinorelbinechemotherapyGastroenterologymethotrexatevinca alkaloidsYoung Adultchemotherapy; desmoid; familial adenomatosis polyposis; methotrexate; vinca alkaloidsLow-dose chemotherapyInternal medicinemedicineHumansChemotherapyChildeducationDesmoidSurvival analysisRetrospective StudiesChemotherapyeducation.field_of_studybiologybusiness.industryFamilial adenomatosis polyposisbiology.organism_classificationmedicine.diseasefamilial adenomatosis polyposisMethotrexateAdenomatous Polyposis ColiOncologyFemaleSarcomabusinessProgressive diseasemedicine.drug
researchProduct

Efficacy of weekly low-dose chemotherapy in elderly women with advanced ovarian cancer: is there an antiangiogenic effect?

2006

13133 Background: In elderly patients decreased functionality of multiple organ systems may affect pharmacokinetics and pharmacodynamics of drugs. For this reason elderly cancer patients experience enhanced susceptibility to common chemotherapy-related adverse events. A way to prevent these effects could be metronomic chemotherapy, which is a variation of dose-dense therapy, with a cumulative dose significantly lower than maximum tolerated dose. Methods: 27 advanced ovarian cancer patients, median age 67 (range 60–86), received low dose weekly continuous chemotherapy until disease progression. All patients were treated with CBDCA AUC 2 mg/ml/min and Docetaxel 35 mg/sqm (adjusted according …

OncologyCancer Researchmedicine.medical_specialtyAdvanced ovarian cancerbusiness.industryCancermedicine.diseaseOncologyAntiangiogenic effectPharmacokineticsLow-dose chemotherapyInternal medicinemedicinebusinessOrgan systemJournal of Clinical Oncology
researchProduct